AOD-9604 is a small fragment of the growth hormone molecule and does not appear to significantly increase GH or IGF-1 levels
The downstream effects include impaired methylation, elevated homocysteine, reduced neurotransmitter synthesis, and poor cellular energy
All three medications are approved by the FDA, but they have different doses and applications tailored to specific health conditions and populations.7 Other FDA approved GLP-1 receptor agonists for glycemic control include Dulaglutide SC (Trulicity), Exenatide injectable solution SC (Byetta), Exenatide injectable suspension SC, Liraglutide SC (Victoza), Liraglutide/insulin degludec (Xultophy), Lixisenatide/insulin glargine (Soliqua), and Tirzepatide (Mounjaro), which is also a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
We often find that balancing hormones with Bioidentical Hormone Replacement Therapy is a great first step
Ghosh, A., Biswas, A., Sadhukhan, T., Das, S
Liraglutide-induced increases in the microtubule-associated protein 1A/1B-light chain 3 (LC3)-II expression and p62 degradation were prevented by the compound C-mediated inhibition of AMPK